Investor Insights

This summary was created by AI, based on 3 opinions in the last 12 months.

Royalty Pharma plc (RPRX-Q) has garnered attention from multiple analysts, all of whom identify it as a top pick in the pharmaceutical sector. The company operates uniquely by holding investments in jointly developed royalty products, allowing it to engage with major pharmaceutical firms. Analysts highlight its substantial returns on investments, such as a recent $230 million monetization yielding a 76% ROI, strengthening its financial position for debt repayment and product development. With appealing earnings multiples and a solid return on equity, the stock offers a good dividend yield, further supported by a low payout ratio. Experts suggest upward revisions for stop-loss levels and provide optimistic price targets, indicating a potential upside of around 25% while maintaining strong growth in their portfolio.

Consensus
Positive
Valuation
Undervalued
Similar
Bristol-Myers, BMY
premium

This is a Panic-proof Portfolio opinion which is available only for Premium members

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

TOP PICK
Stockchase Research Editor: Michael O’Reilly

We reiterate RPRX as a TOP PICK.  This unique pharma company has investments in 35 jointly developed royalty products, with the largest pharma companies and has several new joint products in development.  It trades at 17x earnings, 2.1x book and supports a 12% ROE.  We recommend trailing up the stop (from $26) to $29, looking to achieve $41 — upside potential of 25%.  Yield 2.6%

(Analysts’ price target is $41.00)
premium

This is a Panic-proof Portfolio opinion which is available only for Premium members

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

TOP PICK
Stockchase Research Editor: Michael O'Reilly

We reiterate RPRX as a TOP PICK.  The company is the largest holder of pharma based royalties, providing late stage funding for forward cash royalties.  The company just monetized a recent investment that netted $230 million -- a 76% return on investment -- allowing for a pay down in debt, continuation in share buy backs, and further product development.  The company trades at 8x earnings, 1.8x book and supports a ROE of 24%.  We recommend trailing up the stop (from $22) to $26, looking to achieve $40 -- upside potential of 25%.  Yield 2.6% 

premium

This is a Panic-proof Portfolio opinion which is available only for Premium members

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

TOP PICK
Stockchase Research Editor: Michael O'Reilly

RPRX partners with pharma companies like Bristol-Myers to help fund development in exchange for collecting royalties.  It pays a good dividend, backed by a payout ratio under 33% of cash flow.  It trades at 10x earnings, under 2x book and supports a 17% ROE.  Its portfolio grew by 15% this year. We recommend setting a stop-loss at $22, looking to achieve $33 -- upside potential of 28%.  Yield 3.2%

(Analysts’ price target is $41.53)
BUY
Trades cheaply and is now going higher after being stuck for two years. He always said to stick by this.
WATCH
Invests in biotech and pharma companies in exchange for a royalty. He tracks this one, with its 25B market cap.
Showing 1 to 5 of 5 entries
  • «
  • 1
  • »

Royalty Pharma plc(RPRX-Q) Rating

Ranking : 1 out of 5

Bullish - Buy Signals / Votes : 0

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 0

Total Signals / Votes : 0

Stockchase rating for Royalty Pharma plc is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Royalty Pharma plc(RPRX-Q) Frequently Asked Questions

What is Royalty Pharma plc stock symbol?

Royalty Pharma plc is a American stock, trading under the symbol RPRX-Q on the NASDAQ (RPRX). It is usually referred to as NASDAQ:RPRX or RPRX-Q

Is Royalty Pharma plc a buy or a sell?

In the last year, there was no coverage of Royalty Pharma plc published on Stockchase.

Is Royalty Pharma plc a good investment or a top pick?

Royalty Pharma plc was recommended as a Top Pick by on . Read the latest stock experts ratings for Royalty Pharma plc.

Why is Royalty Pharma plc stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Royalty Pharma plc worth watching?

0 stock analysts on Stockchase covered Royalty Pharma plc In the last year. It is a trending stock that is worth watching.

What is Royalty Pharma plc stock price?

On 2025-04-02, Royalty Pharma plc (RPRX-Q) stock closed at a price of $31.28.